Additionally, the NSP can reverse the HCC-induced reduction of p53 expression, and SOR/Nps combination therapy reduces SOR resistance in HCC by inhibiting the activation of PPAR- and FOXO-1 and lowering Ki-67 and inflammatory cytokines. The gene discussed is PPARA; the disease is hepatocellular carcinoma.